- Home
- XOMAP vs MANH Comparison
XOMAP vs MANH Comparison
Compare XOMAP & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- MANH
- Stock Information
- Founded
- XOMAP N/A
- MANH 1990
- Country
- XOMAP United States
- MANH United States
- Employees
- XOMAP 13
- MANH N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- MANH Computer Software: Prepackaged Software
- Sector
- XOMAP Health Care
- MANH Technology
- Exchange
- XOMAP Nasdaq
- MANH Nasdaq
- Market Cap
- XOMAP N/A
- MANH N/A
- IPO Year
- XOMAP N/A
- MANH 1998
- Fundamental
- Price
- XOMAP $25.65
- MANH $196.16
- Analyst Decision
- XOMAP
- MANH Buy
- Analyst Count
- XOMAP 0
- MANH 9
- Target Price
- XOMAP N/A
- MANH $208.88
- AVG Volume (30 Days)
- XOMAP N/A
- MANH 569.8K
- Earning Date
- XOMAP N/A
- MANH 07-22-2025
- Dividend Yield
- XOMAP N/A
- MANH N/A
- EPS Growth
- XOMAP N/A
- MANH 14.38
- EPS
- XOMAP N/A
- MANH 3.50
- Revenue
- XOMAP N/A
- MANH $1,050,587,000.00
- Revenue This Year
- XOMAP N/A
- MANH $3.90
- Revenue Next Year
- XOMAP N/A
- MANH $7.11
- P/E Ratio
- XOMAP N/A
- MANH $57.07
- Revenue Growth
- XOMAP N/A
- MANH 9.18
- 52 Week Low
- XOMAP N/A
- MANH $140.81
- 52 Week High
- XOMAP N/A
- MANH $312.60
- Technical
- Relative Strength Index (RSI)
- XOMAP 48.21
- MANH 52.38
- Support Level
- XOMAP $25.64
- MANH $194.52
- Resistance Level
- XOMAP $26.05
- MANH $204.09
- Average True Range (ATR)
- XOMAP 0.10
- MANH 4.40
- MACD
- XOMAP -0.00
- MANH 0.03
- Stochastic Oscillator
- XOMAP 46.67
- MANH 56.83
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.